November 4, 2025 — Leads & Copy —
Arcturus Therapeutics Holdings Inc. (ARCT) will participate in upcoming investor conferences, including the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12 at 11:30 a.m. ET and the Jefferies Global Healthcare Conference in London from November 17-20.
Arcturus, founded in 2013 and based in San Diego, is a commercial mRNA medicines and vaccines company. Its technologies include LUNAR® lipid-mediated delivery, STARR® mRNA technology (sa-mRNA), and mRNA drug substance and product manufacturing expertise. Arcturus developed KOSTAIVE®, the first approved self-amplifying messenger RNA (sa-mRNA) COVID vaccine.
The company collaborates with CSL Seqirus for mRNA vaccines and has a joint venture in Japan, ARCALIS, for manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates for OTC deficiency and cystic fibrosis (CF), plus partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza.
Arcturus’ platforms can be applied toward multiple types of nucleic acid medicines and its technologies are covered by over 500 patents and patent applications. For more information, visit www.ArcturusRx.com.
Source: Arcturus Therapeutics Holdings Inc.
